215 related articles for article (PubMed ID: 34818414)
1. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T; Kumar S; Shimono J; Daenthanasanmak A; Dubois S; Lin Y; Bryant B; Petrus MN; Bachy E; Huang DW; Yang Y; Green PL; Hasegawa H; Maeda M; Goto H; Endo T; Yokota T; Hatanaka KC; Hatanaka Y; Tanaka S; Matsuno Y; Yang Y; Hashino S; Teshima T; Waldmann TA; Staudt LM; Nakagawa M
Blood; 2022 Mar; 139(10):1541-1556. PubMed ID: 34818414
[TBL] [Abstract][Full Text] [Related]
2. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract][Full Text] [Related]
3. Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).
Xu X; Kalac M; Markson M; Chan M; Brody JD; Bhagat G; Ang RL; Legarda D; Justus SJ; Liu F; Li Q; Xiong H; Ting AT
Cell Death Dis; 2020 Feb; 11(2):94. PubMed ID: 32024820
[TBL] [Abstract][Full Text] [Related]
4. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
[TBL] [Abstract][Full Text] [Related]
5. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.
Chung EY; Mai Y; Shah UA; Wei Y; Ishida E; Kataoka K; Ren X; Pradhan K; Bartholdy B; Wei X; Zou Y; Zhang J; Ogawa S; Steidl U; Zang X; Verma A; Janakiram M; Ye BH
Clin Cancer Res; 2019 Jun; 25(12):3589-3601. PubMed ID: 30862694
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Eur J Pharmacol; 2020 Apr; 872():172953. PubMed ID: 31996318
[TBL] [Abstract][Full Text] [Related]
7. Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy.
Ishikawa C; Senba M; Mori N
Invest New Drugs; 2021 Apr; 39(2):317-329. PubMed ID: 32959166
[TBL] [Abstract][Full Text] [Related]
8. Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2017 Aug; 51(2):633-643. PubMed ID: 28586006
[TBL] [Abstract][Full Text] [Related]
9. Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.
Chilmi S; Nakahata S; Fauzi YR; Ichikawa T; Tani C; Suwanruengsri M; Yamaguchi R; Matsuura T; Kurosawa G; Morishita K
Int J Hematol; 2020 Oct; 112(4):496-503. PubMed ID: 32656636
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.
Rauch DA; Olson SL; Harding JC; Sundaramoorthi H; Kim Y; Zhou T; MacLeod AR; Challen G; Ratner L
Retrovirology; 2020 Aug; 17(1):27. PubMed ID: 32859220
[TBL] [Abstract][Full Text] [Related]
11. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.
Morichika K; Karube K; Kayo H; Uchino S; Nishi Y; Nakachi S; Okamoto S; Morishima S; Ohshiro K; Nakazato I; Fukushima T; Masuzaki H
Cancer Sci; 2019 Sep; 110(9):2982-2991. PubMed ID: 31237072
[TBL] [Abstract][Full Text] [Related]
13. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
14. Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region.
Ashrafi F; Rahimzada M; Parandi M; Mirhosseini A; Mashkani B; Ahmadi Ghezeldasht S; Soltani A; Rafatpanah H; Mosavat A; Abdolrahim Rezaee S
Gene; 2022 Dec; 847():146885. PubMed ID: 36108787
[TBL] [Abstract][Full Text] [Related]
15. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).
Hatta Y; Koeffler HP
Leukemia; 2002 Jun; 16(6):1069-85. PubMed ID: 12040438
[TBL] [Abstract][Full Text] [Related]
16. WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells.
Moles R; Bai XT; Chaib-Mezrag H; Nicot C
J Hematol Oncol; 2016 Nov; 9(1):121. PubMed ID: 27829440
[TBL] [Abstract][Full Text] [Related]
17. Cell signaling modifiers for molecular targeted therapy in ATLL.
Mori N
Front Biosci (Landmark Ed); 2009 Jan; 14(4):1479-89. PubMed ID: 19273141
[TBL] [Abstract][Full Text] [Related]
18. Karyotypic complexity, TP53 pathogenic variants, and increased number of variants on Next-Generation Sequencing are associated with disease progression in a North American Adult T-Cell Leukemia/Lymphoma cohort.
Zhang X; Shi Y; Ramesh KH; Naeem R; Wang Y
Int J Lab Hematol; 2021 Aug; 43(4):651-657. PubMed ID: 33988304
[TBL] [Abstract][Full Text] [Related]
19. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma.
Hodson A; Crichton S; Montoto S; Mir N; Matutes E; Cwynarski K; Kumaran T; Ardeshna KM; Pagliuca A; Taylor GP; Fields PA
J Clin Oncol; 2011 Dec; 29(35):4696-701. PubMed ID: 22042945
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.
Fauzi YR; Nakahata S; Chilmi S; Ichikawa T; Nueangphuet P; Yamaguchi R; Nakamura T; Shimoda K; Morishita K
PLoS One; 2021; 16(8):e0256320. PubMed ID: 34407152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
